pH Imaging in Multiple Sclerosis

• Status: Not yet recruiting
• Trial end date: 0000-00-00
• Target enrollment: 20
• Participant gender: All

Summary

Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a 1-hour brain scan for both patients and controls. In the first 6 months of the study, investigators will develop and test a uMT-based APT imaging for brain tissue pH measurement and use a hypercapnia paradigm to validate the tissue pH changes between breathing room air and 5% CO2 (by increasing tissue acidity) inhalation. With implementation of hypercapnia MRI, pH-weighted imaging will be validated for its robustness and reproducibility.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York University School of Medicine
• Last Updated: 2017-04-19

Criteria

Inclusion Criteria:

• Healthy male or female non-MS control volunteers

Exclusion Criteria:

• Medically unstable or with cardiac, pulmonary, hematological, renal, or hepatic dysfunction.

• Current or past DSM-IV diagnosis of major depression, bipolar and psychotic disorders.

• Contraindications for MRI, including

• Intracranial clips

• Metal implants

• External metallic devices/objects/clips within 10mm of the head

• Suspected or confirmed metal in the eyes (history of welding or similar activity)

• Claustrophobia

• Cardiac pacemaker or pacing wires

• Pregnancy - Pregnancy tests will be offered to women of childbearing age at no cost to the subject

• History of moderate to severe head injury, stroke, and seizures.

• Alcoholism or drug dependency.

• Renal or liver disease as this may cause concerns related to Gd-DTPA contrast agent.

• Allergy to the contrast agent Gadolinium

• Relapses or steroid therapy in patient at or in the month preceding the study

• Patients only